Climb Biotherapeutics, Inc. (CLYM)
Market Open
15 Jun, 14:41
NASDAQ (NMS) NASDAQ (NMS) Primary $
11. 48
+0.04
+0.3497%
$
780.03M Market Cap
- P/E Ratio
- Div Yield
122,112 Volume
0 Eps
$ 11.44
Previous Close 
Want to track CLYM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Climb Biotherapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LG Leland Gershell Oppenheimer | 10,216.31 | $100,091.94 | $116,670.22 | $16,578.28 | 16.56% |
| DB Danielle Brill Truist Securities | 823.06 | $6,149.05 | $9,333.49 | $3,184.44 | 51.79% |
| JH Julian Harrison BTIG | 367.46 | $2,910.3 | $4,163.28 | $1,252.98 | 43.05% |
| GL Geulah Livshits Chardan Capital | 2,399.84 | $27,330.49 | $27,550.19 | $219.7 | 0.8% |
| JC Joseph Catanzaro Mizuho | 854.14 | $7,450.92 | $9,805.52 | $2,354.6 | 31.6% |
